|Day Low/High||1.51 / 1.62|
|52 Wk Low/High||1.50 / 5.99|
Additional Clinical Trials Evaluating Combinations with Aldoxorubicin Expected to Commence in 2018
Hires Investigation Firm to Initiate Short Selling Audit
Company's Goal is to Create a New Class of Rationally Designed, Breakthrough Anti-Cancer Drugs
Shares of Common Stock Will Begin Trading on a Post-Split Basis on November 1, 2017
Stockholders Approve Reverse Stock Split Proposal by More Than Double FOR to One AGAINST
Listing Extension Granted Pending Results of Stockholder Vote
- Authorized Common and Preferred Shares to be Reversed on Same One-for-Six Ratio as Issued and Outstanding Shares
Company Seeks to Avoid Delisting from NASDAQ
NantCell to Expand the Development of Aldoxorubicin into Multiple Tumor Types in Combination with Immuno-Oncology and Cell-Based Therapies
Investors in CytRx Corp saw new options begin trading today, for the March 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
- Dr. Shanta Chawla promoted to Senior Vice President of Drug Development -
- Current Clinical and Preclinical Data Can Support Approval
Hope springs eternal, until it's dashed on the rocks and buried at sea.
Oral Presentation Highlighting Updated and More Detailed Results from Global Phase 3 Trial in STS
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.